Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)

NCT02615067 is registered in ClinicalTrials.gov with Molecular Insight Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02615067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02615067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2015
Completion date
December 28, 2017
Enrollment
531 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer